Loading...
Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook
AN
AnalystHighTarget
Not Invested
Community Contributor
Published
03 Feb 26
Views
9
03 Feb
US$11.82
AnalystHighTarget's Fair Value
US$40.00
70.5% undervalued intrinsic discount1Y
-18.1%7D
24.9%1Y
-18.1%7D
24.9%You can edit this narrative until Feb 4 11:15 AM. Then, changes will post as Updates.
Author's Valuation
US$4070.5% undervalued intrinsic discount
AnalystHighTarget Fair Value